Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently have a $8.00 price target on the stock. Needham & Company LLC's price objective points to a potential upside of 51.52% from the stock's previous close.
Separately, Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 target price for the company. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $7.00.
Check Out Our Latest Stock Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Stock Down 7.7%
RXRX traded down $0.44 during trading on Tuesday, hitting $5.28. 31,496,533 shares of the company's stock were exchanged, compared to its average volume of 16,582,415. The company has a quick ratio of 4.11, a current ratio of 4.11 and a debt-to-equity ratio of 0.02. The business's 50 day moving average is $4.81 and its two-hundred day moving average is $6.07. Recursion Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The stock has a market cap of $2.15 billion, a P/E ratio of -2.98 and a beta of 0.91.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The business had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.39) EPS. As a group, equities analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Recursion Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC grew its position in Recursion Pharmaceuticals by 83.7% during the second quarter. Farther Finance Advisors LLC now owns 14,202 shares of the company's stock valued at $72,000 after buying an additional 6,470 shares during the period. Rhumbline Advisers grew its position in Recursion Pharmaceuticals by 7.5% during the first quarter. Rhumbline Advisers now owns 359,175 shares of the company's stock valued at $1,900,000 after buying an additional 25,143 shares during the period. Focus Partners Wealth bought a new position in Recursion Pharmaceuticals during the first quarter valued at about $77,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Recursion Pharmaceuticals by 183.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company's stock valued at $33,901,000 after buying an additional 4,149,346 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Recursion Pharmaceuticals by 7.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company's stock valued at $953,000 after buying an additional 12,372 shares during the period. Institutional investors own 89.06% of the company's stock.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Recommended Stories

Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.